受注:045-509-1970 |
技術サポート:[email protected] 平日9:00〜18:00 1営業日以内にご連絡を差し上げます |
製品コード:A2028 Batch: A202805
Tiragolumab (anti-TIGIT) (RG6058, MTIG7192A) is a humanized IgG1/kappa monoclonal antibody that binds TIGIT to prevent its interaction with its ligand PVR (CD155).
CAS No. | 1918185-84-8 |
---|---|
Isotype | Human IgG1, κ |
Source | CHO cells |
Storage (From the date of receipt) |
Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles. |
Shipping | Shipped under low temperature conditions |
Purity | 99% |
Protein concentration | 12.27mg/ml |
Endotoxin Level | <1EU/mg |
The immune checkpoint TIGIT/CD155 promotes the exhaustion of CD8 + T cells in TNBC through glucose metabolic reprogramming mediated by PI3K/AKT/mTOR signaling [ Cell Commun Signal, 2024, 22(1):35] | PubMed: 38216949 |
Chemotherapy induces myeloid-driven spatial T-cell exhaustion in ovarian cancer [ bioRxiv, 2024, 2024.03.19.585657] | PubMed: 38562799 |
Knockout of the inhibitory receptor TIGIT enhances the antitumor response of ex vivo expanded NK cells and prevents fratricide with therapeutic Fc-active TIGIT antibodies [ J Immunother Cancer, 2023, 11(12)e007502] | PubMed: 38081778 |
人間や獣医の診断であるか治療的な使用のためにでない。